Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
JAMA · 05.12.2023 · 330 (21) · 2064
DOI: 10.1001/jama.2023.19918 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 05.12.2023. Verfasst von Jianming Xu und 31 weiteren Autor:innen. Beteiligte Einrichtung: The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Esophagogastric Junction, Stomach Neoplasms. Die Arbeit wurde bisher 434-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, and few effective treatments are available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to programmed cell death 1 (PD-1), in combination with chemotherapy, has demonstrated promising efficacy.
Objective
To compare overall survival of patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancers who were treated with sintilimab with chemotherapy vs placebo with chemotherapy. Also compared were a subset of patients with a PD ligand 1 (PD-L1) combined positive score (CPS) of 5 or more (range, 1-100). Design, Setting, and Participants Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 62 hospitals in China that enrolled 650 patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma between January 3, 2019, and August 5, 2020. Final follow-up occurred on June 20, 2021.
Interventions
Patients were randomized 1:1 to either sintilimab (n = 327) or placebo (n = 323) combined with capecitabine and oxaliplatin (the XELOX regimen) every 3 weeks for a maximum of 6 cycles. Maintenance therapy with sintilimab or placebo plus capecitabine continued for up to 2 years. Main Outcomes and Measures The primary end point was overall survival time from randomization.
Results
Of the 650 patients (mean age, 59 years; 483 [74.3%] men), 327 were randomized to sintilimab plus chemotherapy and 323 to placebo plus chemotherapy. Among the randomized patients, 397 (61.1%) had tumors with a PD-L1 CPS of 5 or more; 563 (86.6%) discontinued study treatment and 388 (59.7%) died; 1 patient (<0.1%) was lost to follow-up. Among all randomized patients, sintilimab improved overall survival compared with placebo (median, 15.2 vs 12.3 months; stratified hazard ratio [HR], 0.77 [95% CI, 0.63-0.94]; P = .009). Among patients with a CPS of 5 or more, sintilimab improved overall survival compared with placebo (median, 18.4 vs 12.9 months; HR, 0.66 [95% CI, 0.50-0.86]; P = .002). The most common grade 3 or higher treatment-related adverse events were decreased platelet count (sintilimab, 24.7% vs placebo, 21.3%), decreased neutrophil count (sintilimab, 20.1% vs placebo, 18.8%), and anemia (sintilimab, 12.5% vs placebo, 8.8%). Conclusions and Relevance Among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma treated with first-line chemotherapy, sintilimab significantly improved overall survival for all patients and for patients with a CPS of 5 or more compared with placebo. Trial Registration ClinicalTrials.gov Identifier: NCT03745170
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
- The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
- Anhui Provincial Hospital, Hefei, China.
- The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Henan Provincial People's Hospital, Zhengzhou, China.
- Affiliated Hospital of Jining Medical University, Jining, China.
Zitieren
APA
Xu, J., Jiang, H., Pan, Y., Gu, K., Cang, S., Han, L., Shu, Y., Li, J., Zhao, J., Pan, H., Luo, S., Qin, Y., Guo, Q., Bai, Y., Ling, Y., Yang, J., Yan, Z., Yang, L., Tang, Y., …, & ORIENT-16 Investigators (2023). Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer. JAMA, 330(21), 2064. https://doi.org/10.1001/jama.2023.19918
Vancouver
Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer. JAMA. 2023;330(21):2064. doi:10.1001/jama.2023.19918
BibTeX
@article{Xu2023,
author = {Xu, Jianming and Jiang, Haiping and Pan, Yueyin and Gu, Kangsheng and Cang, Shundong and Han, Lei and Shu, Yongqian and Li, Jiayi and Zhao, Junhui and Pan, Hongming and Luo, Suxia and Qin, Yanru and Guo, Qunyi and Bai, Yuxian and Ling, Yang and Yang, Jianwei and Yan, Zhilong and Yang, Lei and Tang, Yong and He, Yifu and Zhang, Liangming and Liang, Xinjun and Niu, Zuoxing and Zhang, Jingdong and Mao, Yong and Guo, Yingmei and Peng, Bo and Li, Ziran and Liu, Ying and Wang, Yan and Zhou, Hui and ORIENT-16 Investigators, ORIENT-16 Investigators},
title = {Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer},
journal = {JAMA},
year = {2023},
volume = {330},
number = {21},
pages = {2064},
doi = {10.1001/jama.2023.19918}
}
EUVIMED